BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26020124)

  • 21. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
    Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
    Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
    Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
    Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
    Shi C; Tian R; Wang M; Wang X; Jiang J; Zhang Z; Li X; He Z; Gong W; Qin R
    Cancer Biol Ther; 2010 Dec; 10(11):1182-90. PubMed ID: 20948317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
    Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
    Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
    Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
    Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y
    Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
    Cui F; Wang J; Chen D; Chen YJ
    Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
    Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
    Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.
    Miki J; Furusato B; Li H; Gu Y; Takahashi H; Egawa S; Sesterhenn IA; McLeod DG; Srivastava S; Rhim JS
    Cancer Res; 2007 Apr; 67(7):3153-61. PubMed ID: 17409422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
    Sarvi S; Mackinnon AC; Avlonitis N; Bradley M; Rintoul RC; Rassl DM; Wang W; Forbes SJ; Gregory CD; Sethi T
    Cancer Res; 2014 Mar; 74(5):1554-65. PubMed ID: 24436149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.
    Yun X; Zhang K; Wang J; Pangeni RP; Yang L; Bonner M; Wu J; Wang J; Nardi IK; Gao M; Raz DJ
    Mol Cancer Res; 2018 Jul; 16(7):1161-1171. PubMed ID: 29720480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a subpopulation of long-term tumor-initiating cells in colon cancer.
    Peng L; Xiong Y; Wang R; Xiang L; Zhou H; Gu H
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
    Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
    J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant microRNAs expression in CD133⁺/CD326⁺ human lung adenocarcinoma initiating cells from A549.
    Lin S; Sun JG; Wu JB; Long HX; Zhu CH; Xiang T; Ma H; Zhao ZQ; Yao Q; Zhang AM; Zhu B; Chen ZT
    Mol Cells; 2012 Mar; 33(3):277-83. PubMed ID: 22349807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases.
    Yano S; Tazawa H; Hashimoto Y; Shirakawa Y; Kuroda S; Nishizaki M; Kishimoto H; Uno F; Nagasaka T; Urata Y; Kagawa S; Hoffman RM; Fujiwara T
    Clin Cancer Res; 2013 Dec; 19(23):6495-505. PubMed ID: 24081978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
    Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
    Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.